Celltrion opens new UK headquarters in Uxbridge, UK
LONDON, June 19, 2025--(BUSINESS WIRE)--Celltrion UK has officially opened its new UK headquarters at the Charter Building in Uxbridge, UK, reinforcing the company's dedication to long-term growth and partnership in the UK market.
The opening ceremony was attended by Hyoung-Ki Kim, CEO and Vice Chairman at Celltrion, Rosalind Campion, Director of the Office for Life Sciences and Mark Samuels, Chief Executive of Medicines UK, and the British Biosimilars Association. The event was marked with a ribbon cutting ceremony.
Strategically located in the heart of Uxbridge, the new office will serve as Celltrion UK's central hub for UK operations. This move places Celltrion among a growing list of life sciences companies including Regeneron, Amgen, Gilead Sciences, Daiichi Sankyo, that have established presence in Uxbridge – emerging as a leading hub for biotechnology and pharmaceutical innovation.
Speaking at the opening ceremony, Hyoung-Ki Kim, CEO and Vice Chairman of Celltrion, said, "The opening our new UK office marks a pivotal milestone in Celltrion UK history. This demonstrates our strong commitment to the UK, a strategic market for our growth. We are here for the long term and are invested in the future of biosimilars in the UK. We look forward to continued collaboration with local institutions and regulatory bodies to ensure sustainable access to high-quality biologic treatments."
Rosalind Campion, Director of the Office for Life Sciences, added, "With the NHS prescribing already 80% generic by volume, the next frontier is Biosimilars. This is a pivotal time for the sector just before the introduction of the life sciences sector plan and the NHS 10 year plan."
Mark Samuels, chief executive of Medicines UK, said, "Celltrion's medicines are a critical part of the UK life sciences ecosystem, and I am delighted that the company is strengthening its investment in the UK with a new office, supporting British jobs and the supply of essential medicines for the NHS."
The new headquarters also reflects continued growth for Celltrion UK, which has expanded its headcount by 20% over the past year. With an exciting pipeline of new products spanning across multiple therapeutic areas including allergy, endocrinology, ophthalmology and immunology anticipated over the coming years, the company expects further recruitment and investment in the coming years.
This move is the latest chapter in Celltrion's long-term vision for the UK, demonstrating its dedication to being a trusted healthcare partner, a contributor to the UK economy, and a key player in the global biosimilars market.
Notes to Editors:
About Celltrion
Celltrion is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world's first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website www.celltrion.com/en-us and stay updated with our latest news and events on our social media - LinkedIn, Instagram, X, and Facebook.
About Celltrion Healthcare UK Limited (Celltrion UK)
Celltrion UK is committed to delivering innovative and affordable medications to promote patients' access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the Medicines and Healthcare products Regulatory Agency (MHRA) regulations. For more information, please visit: https://www.celltrionhealthcare.co.uk/
FORWARD-LOOKING STATEMENT
Certain information set forth in this press release contains statements related to our future business, and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws.
These statements may be identified by words such as "prepares," "hopes to," "upcoming," "plans to," "aims to," "to be launched," "is preparing," "once gained," "could," "with the aim of," "may," "once identified," "will," "working towards," "is due," "become available," "has potential to," the negative of these words or such other variations thereon or comparable terminology.
In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries' management, of which many are beyond its control.
Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.
Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements.
Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250618970259/en/
Contacts
For further information please contact: Donna Gandhidgandhi@hanovercomms.com +44 (0) 203 817 6591
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
23 minutes ago
- Bloomberg
Qube to Enter US After Building $30 Billion Hedge Fund Empire
In roughly seven years, Qube Research & Technologies has grown into a hedge fund powerhouse without setting foot in the US — the industry's mecca. That's about to change now. London-based QRT is preparing to start an office in Houston, Texas, according to people with knowledge of the matter. The office will add to its global presence spanning Sydney to Hong Kong and Dubai to Aarhus in Denmark, the people said, asking not to be identified because the details are private.
Yahoo
26 minutes ago
- Yahoo
Elliott-owned housebuilder Avant clinches deal with lenders
A major British housebuilder owned by the prominent investor Elliott Management has clinched a refinancing deal with its lenders amid growing financial pressure on the industry over cladding-related liabilities. Sky News has learnt that Avant Homes, which has been owned by Elliott since 2021, has reached an agreement with a syndicate of lenders to provide additional financial headroom to the company. Details of the refinancing were unclear on Tuesday, although a source close to Elliott insisted that it had not committed any new capital to Avant as part of it. Avant sold more than 1,750 homes in the year to 30 June 2023, the last for which results are available, and recorded revenue of almost £500m. However, in recent months there has been growing industry speculation about the company's financial health as cladding-related exposures hit housebuilders across the industry. In recent weeks, investment bankers have been canvassing interest from rival housebuilders about a takeover of Avant, although sources close to Elliott and Avant denied that any such process was being conducted on their behalf. Avant is chaired by Jeff Fairburn, who left Persimmon in 2018 amid a City outcry over his vast pay package. Elliott's deal to buy Avant was engineered through Berkeley DeVeer, in which it was already a shareholder. Last year, Sky News revealed that Avant had tabled an offer to acquire the London-listed housebuilder Crest Nicholson, although the proposal was ultimately unsuccessful. Avant and Elliott both declined to comment.
Los Angeles Times
26 minutes ago
- Los Angeles Times
Ukrainians welcome U.S. aid but see Trump's 50-day ultimatum to Putin as too long
KYIV, Ukraine — Ukrainians welcomed President Trump's pledge of more U.S.-made weapons in their three-year fight against Russia's invasion, though it is unclear what exactly they will get and how quickly. The time frame for the further arms deliveries, which European countries have agreed to pay for, is crucial. Russia is making a summer push to break through along the 620-mile front line, and its drones and missiles are hammering Ukrainian cities more than at any time in the war. Ukrainian President Volodymyr Zelensky thanked Trump for his 'willingness to support Ukraine.' In Kyiv, resident Nina Tokar, 70, said Tuesday that with more U.S. weapons going to Ukraine 'maybe this will all end faster.' However, following Trump's threat late last week to impose major sanctions on Russia for failing to reach a deal to end the fighting, the president said Monday that Moscow would get 50 days to come to a settlement or face 'very severe' economic sanctions. While some believe strict tariffs on Moscow could be a game changer, the decision to postpone them until September struck some European observers as being too long. Ukrainian officials made no direct comment about the 50-day window, but for Russia, the delay of new sanctions came as a reprieve. Senior Russian lawmaker Konstantin Kosachev commented: 'Oh, how much can change both on the battlefield and with the mood of those leading the U.S. and NATO in 50 days.' Russian President Vladimir Putin hasn't budged when presented with previous U.S. deadlines and threats. In an interview with the BBC broadcast Tuesday, Trump said of Putin: 'I'm disappointed in him, but I'm not done with him.' Russian Foreign Minister Sergey Lavrov said Moscow 'would like to understand what is behind this statement about 50 days,' noting that the Kremlin has offered to continue direct peace talks with Ukraine. 'Earlier, there were also the deadlines of 24 hours and of 100 days,' Lavrov said during an official trip to China. 'We've seen it all and really would like to understand the motivation of the U.S. president.' An assessment published Tuesday by Chatham House noted that 'the exact details of what has been agreed remain hazy.' 'Putin will continue to judge Trump by his actions, not by his words — and so far, there is little enough action to be seen,' the London-based think tank said. Military experts are trying to figure out whether Russian forces could use the window left by Trump to achieve significant territorial gains. Russian troops are slowly ramming through the Ukrainian defenses in Ukraine's eastern Donetsk region, the main focus of the Russian offensive. They are also trying to carve out a buffer zone along the border with the northeastern Ukrainian regions of Sumy and Kharkiv. Russia currently holds about 20% of Ukraine. Ukraine's depleted army has recently been losing more territory, but there is no sign of a looming collapse on the front line, analysts say. Zelensky said he spoke to Trump after the Republican leader's Oval Office announcement Monday on weapons sales, expressing gratitude for the decision to send more Patriot air defense missiles that are vital to defend Ukrainian cities. 'We discussed … the necessary measures and decisions to provide greater protection for people from Russian attacks and strengthen our positions,' Zelensky said on Telegram. 'We agreed to talk more often and coordinate our steps in the future.' Trump and Zelensky have had a notoriously fraught relationship, and Washington's consent to providing more weaponry has eased Kyiv's worries. Even so, some Ukrainians felt the U.S. decision won't alter the course of the war. 'If we take the situation as a whole, it hardly looks like this will fundamentally change anything,' Kyiv resident Oles Oliinyk, 33, told The Associated Press. Tokar, the Kyiv resident, was also skeptical. 'I have very little faith in (Trump). He says one thing today, and tomorrow he may say something else.' Dutch Foreign Minister Caspar Veldkamp expressed misgivings about the 50-day delay on sanctions. 'I do believe that the 50 days that Mr Trump has announced is rather long. It's up to September 2. I think that's rather long,' he said in Brussels on Tuesday. Much remains to be worked out about how and when the weapons, especially the Patriot systems, will be provided, Denmark's Foreign Minister Lars Løkke Rasmussen said. But, in an indication that Europe is relieved that the U.S. hasn't walked away from the conflict, he added: 'The most important thing is that we now have an American readiness to deliver these most needed weapons.' Some European countries, such as Hungary and Slovakia, still rely heavily on Russia for energy supplies and could be hit hard by Trump's threatened secondary sanctions on countries that buy its oil and gas — an effort to isolate Moscow in the global economy. Lithuania's Foreign Minister Kęstutis Budrys said Trump's 50-day delay was a 'signal for Europe to prepare ourselves, because we still have some member states that are exposed to imports of oil and oil products from Russia.' German Defense Minister Boris Pistorius said it remains to be seen whether Trump's announcement will be a turnaround but 'what is decisive is that the tone has changed.' The president's threat to impose sanctions after 50 days is 'significant progress,' Pistorius told ARD television. Stepanenko and Cook write for the Associated Press. Cook reported from Brussels.
